Protagonist Therapeutics Inc expected to post a loss of 87 cents a share - Earnings Preview

Protagonist Therapeutics

28/10/2022 12:38

* Protagonist Therapeutics Inc  PTGX.OQ   PTGX.O  is
expected
to show a fall in quarterly revenue when it reports  results on
November 1 (estimated). 
    * 
    * ​Refinitiv's mean analyst estimate for Protagonist
Therapeutics
Inc is for a loss of 87 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Protagonist
Therapeutics Inc is $35​, above​ its last closing price
of $8.22. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Jun. 30 2022  -0.91       -0.93      -0.84     Beat    9.4
 Mar. 31 2022  -0.58       -0.63      -0.43     Beat    31.6
 Dec. 31 2021  -0.81       -0.78      -0.77     Beat    1.6​
 Sep. 30 2021  -0.69       -0.67      -0.70     Missed  -4.5
 ​​Jun.        -0.54       -0.55      -0.69     Missed  -26.1
 30 2021                                                
 Mar. 31 2021  -0.56       -0.57      -0.54     Beat    4.9​
 Dec. 31 2020  -0.50       -0.48      -0.48     Met     -0.4
 Sep. 30 2020  -0.61       -0.61      -0.21     Beat    65.7
 This summary was machine generated October 28 at 11:38 GMT.  All
figures in US dollars  unless otherwise stated